EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’
EY Predicts Continued Emphasis On Bolt-On Deals, Partnerships In 2022
Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.
You may also be interested in...
Despite concerns about the impact of the Inflation Reduction Act and constraining factors like inflation, EY believes more than $1.4tn in life sciences industry “firepower” should result in increased deal-making this year.
A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.
News and views from day three of the BIO annual meeting include business development insights, such as Sanofi's global head of BD Alban De La Sabliere's promise that big pharma has no hidden agenda and an AbbVie BD exec's observations that lower company valuations have not led to lower asking prices. Also, BIO chairman and Nkarta CEO Paul Hastings' optimism that biotech will rebound and Venus Williams' Sjogren's disease story draws a crowd.